Policy & Regulation
ProtoKinetix Files for Patent Protection for the Use of AAGP in Transplant Medicine
12 February 2020 - - US-based molecular biotechnology company ProtoKinetix, Inc. (OTCQB: PKTX) recently filed for patent protection for a new application of its AAGP molecule, the company said.

During recent testing at The University of British Columbia, where photo receptors were transplanted into animal models, it was observed that AAGP may have had a role in protecting xenografts and allografts from immune rejection from the host immune system, thereby helping the graft to survive and mature in the transplant recipient.

Immune rejection, leading to graft versus host disease is a primary concern present in almost all transplants, requiring the use of immunosuppressants such as cyclosporin, tacrolimus and rapamycin.

In addition to filing for patent protection, ProtoKinetix has started a major study at Dalhousie University to examine the effects of AAGP in transplant medicine.

By protecting this technology, the company is in a better position to move forward with its research in organ transplantation.

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP) that enhance both engraftment and protection of transplanted cells, tissues and organs used in regenerative medicine.

Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials.

Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions.

In addition, we are studying the potential impact on several cancer therapies.